ACTH/MSH-like peptides inhibit the binding of dopaminergic ligands to the dopamine D2 receptor in vitro

1991 ◽  
Vol 207 (1) ◽  
pp. 43-50 ◽  
Author(s):  
Wouter J. Florijn ◽  
Thijs De Boer ◽  
Jeroen A.D.M. Tonnaer ◽  
Jan W. Van Nispen ◽  
Dirk H.G. Versteeg
2016 ◽  
Vol 31 (6) ◽  
pp. 395-404 ◽  
Author(s):  
Kayoko Kanamitsu ◽  
Ryosuke Arakawa ◽  
Yuichi Sugiyama ◽  
Tetsuya Suhara ◽  
Hiroyuki Kusuhara

Synapse ◽  
2000 ◽  
Vol 37 (1) ◽  
pp. 64-70 ◽  
Author(s):  
Jogeshwar Mukherjee ◽  
Tanjore K. Narayanan ◽  
Bradley T. Christian ◽  
Bingzhi Shi ◽  
Kelly A. Dunigan ◽  
...  

2020 ◽  
Author(s):  
Sayed Ibrar Alam ◽  
Min Gi Jo ◽  
Min Woo Kim ◽  
Noman Bin Abid ◽  
Myeong OK Kim

Abstract Backgroung Brain injury is a major risk factor for the development of chronic neurodegenerative diseases. The disease still lacks a potential candidate to treat brain injury associated neurodegeneration. In the present study we aims to investigate the expression of Dopamin D2 receptor in the cortical region as well as in striatum of the injured mouse brain and further explored the neuroprotective effects of selective D2R agonist quinpirole against brain injury-associated neuropathological events after brain injury.Methods In order to test our hypothesis, a normal mice were subjected into TBI mouse model by producing penetrating injury using scalpel blade. A dose of 1mg/kg of quinpirole was daily injected to the TBI mice via intraperitonally for 7 days after producing injury. Further, the immunoblots and immunohistochemistry analysis were performed for both in vivo and in vitro.Results Our biochemical and immunohistological results demonstrated that brain injury suppresses the expression levels of D2R and deregulate the downstream signaling molecules in the cortex and striatum afte TBI at day 7. Treatment with a selective D2R agonist quinpirole regulates GSK3-β/IL-1β/Akt signaling and reduced neuroinflamation after brain injury. Concomitantly, Quinpirole treatment regulated Blood brain-barrier breakdown, reduced neuronal apoptosis and regulated synaptic dysfunction after brain injury. This is the first evidence, which showed that quinpirole treatment reduced secondary brain injury-induced neuropathological evidence in the cortex via D2R/Akt/GSK3-β signaling pathway. Moreover, our in vitro results demonstrated that quinpirole reversed MCM-mediated deleterious effects and significantly regulated D2R/GSK3-β/Akt level in HT22 cells.Conclusion Our results suggest that regulation of Dopamine D2 receptor via quinpirole would be a promising therapeutic strategy against brain injury-induced neurodegeneration.


2008 ◽  
Vol 10 (2) ◽  
pp. 225-231 ◽  
Author(s):  
Gail J. Pyne-Geithman ◽  
Danielle N. Caudell ◽  
Matthew Cooper ◽  
Joseph F. Clark ◽  
Lori A. Shutter

2001 ◽  
pp. 51-57 ◽  
Author(s):  
P Petrossians ◽  
N Ronci ◽  
H Valdes Socin ◽  
A Kalife ◽  
A Stevenaert ◽  
...  

OBJECTIVES: The authors present a case report that proposes the use of cabergoline treatment in silent ACTH adenoma, an unusual member of the heterogeneous group of the so-called clinically non-functioning pituitary adenomas. DESIGN: Following the clinical and radiological improvement of a recurrent silent ACTH adenoma in a 77-year-old patient treated with cabergoline (0.5 mg every 2 days for 2 years), in vitro studies of the original tumor were performed. METHODS: The original tumor from the patient was studied by in situ hybridization and dopamine D2 receptor autoradiography. It was compared with four macroprolactinomas and two macroadenomas from patients with Cushing's disease. RESULTS: The D2 receptor mRNA signal of the reported case was intense and of the same order of magnitude as that observed in control prolactinomas. Dopamine D2 receptor autoradiography was twice that of control corticotroph adenomas and was close to that observed in prolactinomas. CONCLUSIONS: This is the first description of an in vivo shrinkage of an ACTH silent adenoma under cabergoline. We demonstrate in vitro, the presence of D2 receptors in the primitive tumor in concentrations similar to those found in control prolactinomas. These results suggest that therapeutic trials with cabergoline might be undertaken in recurring cases of ACTH silent tumors and more generally, non-functioning pituitary adenomas.


Sign in / Sign up

Export Citation Format

Share Document